Kyle Doherty

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for Oncology Fellows. He also produces print content for OncologyLive, as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Articles

Oncology Fellows Spotlights Recent Grant and Award Winners

November 6th 2025

Oncology Fellows reports recent hematology/oncology fellows grant and award winners and looks ahead to upcoming grants.

Phase 3 KEYNOTE-905 and IMvigor011 Trials Signal New Standards in MIBC

November 6th 2025

Daniel P. Petrylak, MD, discusses key data in MIBC presented during the 2025 ESMO Congress and previews the 19th Annual New York GU Cancers Congress.

177Lu-edotreotide Displays Efficacy Benefit Across Subgroups in Grade 1/2, SSTR+ GEP-NETs

November 6th 2025

Treatment with 177Lu-edotreotide was linked to improvements in PFS and ORR across subgroups of patients with SSTR-positive GEP-NETs.

Dr Gupta on Avelumab Maintenance in Urothelial Carcinoma With/Without Diabetes Mellitus

November 5th 2025

Shilpa Gupta, MD, discusses data from a subgroup analysis of the phase 3 JAVELIN Bladder 100 and future questions surrounding the use of avelumab maintenance in this setting.

GEP-NET–Focused Research Refines Optimal PRRT Use in Well-Differentiated Disease

November 5th 2025

Rohit Thummalapalli, MD, discusses the treatment paradigm for patients with GEP-NETs and the role of Lutetium Lu 177 dotatate across lines of therapy.

Federal Funding Cuts Hit Cancer Research Despite Public Support

October 31st 2025

Primo Nery Lara, Jr., MD, and Suneel Kamath, MD, discuss the effects of federal cuts to cancer research despite public support for funding this research.

Dr Yuan on the DEMETHER Trial of Induction T-DXd Plus HP Maintenance in HER2+ Breast Cancer

October 30th 2025

Yuan Yuan, MD, PhD, discusses a new treatment approach involving induction T-DXd followed by trastuzumab/pertuzumab maintenance in HER2-positive disease.

Tackling Drug Shortages in Hematologic Oncology Care Requires Nuance and Adaptability

October 30th 2025

Harry P. Erba, MD, PhD, and Jayastu Senapati, MBBS, discuss the effects of drug shortages in hematologic oncology and how to adapt practice when they arise.

Dr Wang on the Efficacy of CNS Bridging Radiotherapy Prior to CAR T in B-Cell Lymphoma

October 30th 2025

Pule Wang, MD, discusses findings from a retrospective study of CNS bridging radiation therapy prior to CAR T-cell therapy in B-cell lymphomas.

Dr Tarantino on Clinical Implications of the neoCARHP Trial in HER2+ Breast Cancer

October 30th 2025

Paolo Tarantino, MD, PhD, discusses the clinical utility of data from the phase 3 neoCARHP trial in patients with HER2-positive early breast cancer.

Dr Visco on the Role of RBAC Dose Reductions for High-Risk MCL

October 30th 2025

Carlo Visco, MD, highlights the clinical relevance of reducing the dose of certain RBAC components when administering this regimen in high-risk MCL.

Dr Randall on Incorporating Ultrasound STS Surveillance Into Clinical Practice

October 30th 2025

R. Lor Randall, MD, FACS, discusses a new STS surveillance algorithm based on findings that show the comparable diagnostic utility of ultrasound and MRI.

Vepugratinib-Based Therapy Displays Potential in Metastatic FGFR3+ Urothelial Cancer

October 29th 2025

Vepugratinib-based treatment was safe and active in FGFR3-altered metastatic urothelial cancer.

Dr Tagawa on the PSMAddition Trial of Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI and ADT in PSMA+ mHSPC

October 29th 2025

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the design the PSMAddition trial of lutetium Lu 177 vipivotide tetraxetan plus ARPI and ADT in mHSPC.

Dr Gupta on Future Directions With Enfortumab Vedotin/Pembrolizumab in Urothelial Carcinoma

October 29th 2025

Shilpa Gupta, MD, discusses future research directions for enfortumab vedotin plus pembrolizumab in urothelial carcinoma.

ICI Use Does Not Significantly Affect EOL Outcomes in HCC

October 29th 2025

Margaret Wheless, MD, discusses findings from a study of end-of-life outcomes and health care resource utilization in ICI-treated HCC.

Novel Program Aims to Provide Patient-Level Clinical Trial Communication Skills to Hematology/Oncology Fellows

October 28th 2025

Carma L. Bylund, PhD, discussed the findings from a pilot study of a fellowship-level program for clinical trial communication skills.

Selumetinib Nets EU Approval for Adult NF1-Associated Plexiform Neurofibromas

October 28th 2025

Selumetinib has received approval in the EU for the management of plexiform neurofibromas in adult patients with neurofibromatosis type 1.

Belzutifan-Based Combinations Meet DFS, PFS End Points in Renal Cell Carcinoma

October 28th 2025

Two belzutifan-based combinations met their respective primary efficacy end points of DFS and PFS in the phase 3 LITESPARK-022 and LITESPARK-011 trials.

Dr Mouhieddine on Future Directions With Ferritin and ALC as Biomarkers in Myeloma

October 28th 2025

Tarek Mouhieddine, MD, discusses future research directions with ferritin and ALC as biomarkers of response to bispecific antibodies in myeloma.